Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 31, 2005
app pub date -
Oct 5, 2004
filing date -
Jan 30, 1997
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention provides a LM609 grafted antibody exhibiting selective binding affinity to .alpha..sub.v.beta..sub.3. The LM609 grafted antibody consists of at least one LM609 CDR grafted heavy chain polypeptide and at least one LM609 CDR grafted light chain polypeptide or functional fragment thereof. Nucleic acids encoding LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of .alpha..sub.v.beta..sub.3. The method consists of contacting .alpha..sub.v.beta..sub.3 with a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to .alpha..sub.v.beta..sub.3. Finally, the invention provides for a method of treating an .alpha..sub.v.beta..sub.3-mediated disease. The method consists of administering an effective amount of a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to .alpha..sub.v.beta..sub.3.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully